Comparing the current results to its competitors, Anaptysbio Inc reported Revenue decrease in the 1 quarter 2026 year on year by -7.98 %, despite the revenue increase by the most of its competitors of 12.47 %, recorded in the same quarter.
Anaptysbio Inc , slower than the average decrease reported by the company's competitors of -29.24 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -29.24 %
Anaptysbio Inc 's Comment on Competition and Industry Peers
The competitive landscape includes the potential benefits and advantages of the company's product candidates and approaches relative to competitors, the success of existing and emerging therapies, regulatory approvals, market acceptance, market size and growth potential, and regulatory developments in the United States and other countries.
November 10, 2025
AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results from its Phase 2 trial for rosnilimab in the treatment of moderate-to-severe ulcerative colitis (UC) have been released. The investigational treatment, while showing a strong safety profile, did not achieve the primary efficacy endpoint of mean change from baseline in modified Mayo Score (mMS) nor the key secondary endpoints of clinical response and clinical remission at Week 12. The placebo rates ob...
May 9, 2024
AnaptysBio, a clinical-stage biotechnology company, has recently reported positive top-line results from their Phase 3 clinical trials involving the experimental drug imsidolimab (IL-36R mAb). Designed to address the challenges posed by generalized pustular psoriasis (GPP), a severe orphan disease known for its potential life-threatening consequences, these trials evaluated the safety and efficacy of imsidolimab. This article aims to provide an analysis of the significant findings from the GEMINI-1 and GEMINI-2 trials and their implications for the future treatment of GPP.Key Findings:The recently concluded Phase 3 trials conducted by AnaptysBio focused on assessing the safety and effectiveness of imsidolim...
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Anaptysbio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Anaptysbio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
